Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide delivery system relative bioavailability crossover study in healthy adults
NL-OMON59200Phase 1Completed
- Sponsor
- VectivBio
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apraglutide (6 arms), sponsored by VectivBio. Primary endpoints: Maximum concentration, Area under the concentration-time curve to infinity and 1 more. Started May 2023; status: completed.
02
Drugs
apraglutide
Beyond the preview
Go deeper on NL-OMON59200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59200.